| Indications | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|
Validive®Radiation induced SOM in OPC |
Phase 2b/3 ready
Phase 2b/3 ready
Discovery complete Phase 2b/3 ready |
Phase 2b/3 ready
Phase 2b/3 ready
Preclinical complete Phase 2b/3 ready |
Phase 2b/3 ready
Phase 2b/3 ready
Phase 1 complete Phase 2b/3 ready |
Phase 2b/3 ready
Phase 2b/3 ready
Phase 2 in progress Phase 2b/3 ready |
Phase 2b/3 ready
Phase 2b/3 ready
Phase 3 not started Phase 2b/3 ready |
| Indications | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|
Camsirubicin (MNPR-201)Advanced Soft Tissue Sarcoma |
Phase 2 Data in Soft Tissue Sarcoma, Collaboration with GEIS for larger Phase 2
Phase 2 Data in Soft Tissue Sarcoma, Collaboration with GEIS for larger Phase 2
Discovery complete Phase 2 Data in Soft Tissue Sarcoma, Collaboration with GEIS for larger Phase 2 |
Phase 2 Data in Soft Tissue Sarcoma, Collaboration with GEIS for larger Phase 2
Phase 2 Data in Soft Tissue Sarcoma, Collaboration with GEIS for larger Phase 2
Preclinical complete Phase 2 Data in Soft Tissue Sarcoma, Collaboration with GEIS for larger Phase 2 |
Phase 2 Data in Soft Tissue Sarcoma, Collaboration with GEIS for larger Phase 2
Phase 2 Data in Soft Tissue Sarcoma, Collaboration with GEIS for larger Phase 2
Phase 1 complete Phase 2 Data in Soft Tissue Sarcoma, Collaboration with GEIS for larger Phase 2 |
Phase 2 Data in Soft Tissue Sarcoma, Collaboration with GEIS for larger Phase 2
Phase 2 Data in Soft Tissue Sarcoma, Collaboration with GEIS for larger Phase 2
Phase 2 in progress Phase 2 Data in Soft Tissue Sarcoma, Collaboration with GEIS for larger Phase 2 |
Phase 2 Data in Soft Tissue Sarcoma, Collaboration with GEIS for larger Phase 2
Phase 2 Data in Soft Tissue Sarcoma, Collaboration with GEIS for larger Phase 2
Phase 3 not started Phase 2 Data in Soft Tissue Sarcoma, Collaboration with GEIS for larger Phase 2 |
| Indications | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|
MNPR-101Severe COVID-19 |
In Collaboration with NorthStar Medical Radioisotopes
In Collaboration with NorthStar Medical Radioisotopes
Discovery in progress In Collaboration with NorthStar Medical Radioisotopes |
In Collaboration with NorthStar Medical Radioisotopes
In Collaboration with NorthStar Medical Radioisotopes
Preclinical not started In Collaboration with NorthStar Medical Radioisotopes |
In Collaboration with NorthStar Medical Radioisotopes
In Collaboration with NorthStar Medical Radioisotopes
Phase 1 not started In Collaboration with NorthStar Medical Radioisotopes |
In Collaboration with NorthStar Medical Radioisotopes
In Collaboration with NorthStar Medical Radioisotopes
Phase 2 not started In Collaboration with NorthStar Medical Radioisotopes |
In Collaboration with NorthStar Medical Radioisotopes
In Collaboration with NorthStar Medical Radioisotopes
Phase 3 not started In Collaboration with NorthStar Medical Radioisotopes |
| Indications | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|
MNPR-101Advanced Solid Cancers |
Pre-IND
Pre-IND
Discovery complete Pre-IND |
Pre-IND
Pre-IND
Preclinical in progress Pre-IND |
Pre-IND
Pre-IND
Phase 1 not started Pre-IND |
Pre-IND
Pre-IND
Phase 2 not started Pre-IND |
Pre-IND
Pre-IND
Phase 3 not started Pre-IND |